Skip to main content

Tenpoint aims to make vision loss reversible

| News

Tenpoint aims to make vision loss reversible


The startup Tenpoint Therapeutics has started operations with a funding round of 70 million US dollars. It works to make vision loss reversible at its locations in London and Allschwil.

Tenpoint Therapeutics has developed a platform that can be used to replace cells damaged with age or disease. This technology aims to make vision loss reversible. The startup established in London with operational headquarters in Allschwil at the Switzerland Innovation Park Basel Area has now announced in a press release that it will start operations with a series A round of financing amounting to 70 million US dollars. Basel Area Business & Innovation supported Tenpoint with its settlement in Allschwil  in the canton of Basel-Landschaft.

The biotech company will now develop cell-based therapies and perform in-vivo cell reprogramming. This makes healthy cells available to replace cells that can no longer function. Tenpoint’s CEO Eddy Anglade stated in the press release that most cases of vision loss are due to damaged or missing tissue, adding that this is why “cell-based therapeutics represent an ideal modality for degenerative ocular diseases.” Tenpoint focuses on addressing the causes of vision loss.

All seed investors that had previously enabled the company to be set up were involved in the funding round. Additionally, a new investor was brought on board in the form of British Patient Capital. Chair of the Board David Guyer commented: “Tenpoint has great potential to lead ophthalmology into a new era, which will fully replace cells lost to degenerative conditions rather than merely endeavoring to slow the processes that drive vision loss.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.